NCT06749691View on ClinicalTrials.gov

Liposomal Irinotecan and Apatinib in ES-SCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 28, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Small Cell Lung Cancer Extensive Stage
Interventions
DRUG

Liposomal Irinotecan and Apatinib

Liposomal Irinotecan in Combination With Apatinib

Trial Locations (1)

310009

RECRUITING

Second Affiliated Hospital of Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER